Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme.
Bioorg Med Chem
; 16(14): 6880-90, 2008 Jul 15.
Article
em En
| MEDLINE
| ID: mdl-18558491
ABSTRACT
Adult T-cell leukemia and tropical spastic paraparesis/HTLV-I-associated myelopathy are only some of the more common end results of an infection with a human T-cell leukemia virus type 1 (HTLV-I). Expanding from our previous reports, we synthesized all different permutations of tetrapeptidic HTLV-I protease inhibitors using at least eight P(3)-cap and five P(1)(')-cap moieties. The inhibitors exhibited over 97% inhibition against HIV-1 protease and a wide range of inhibitory activity against HTLV-I protease.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Peptídeos
/
Inibidores de Proteases
/
Vírus Linfotrópico T Tipo 1 Humano
Limite:
Humans
Idioma:
En
Revista:
Bioorg Med Chem
Ano de publicação:
2008
Tipo de documento:
Article